• TaqI Restriction Endonuclease: Protocols and Practical Guida

  2026-05-04

  TaqI Restriction Endonuclease enables rapid, sequence-specific DNA digestion for plasmid, PCR product, and genomic DNA workflows. It is best suited for applications where fast, reliable sticky-end generation is critical, but should not be used in diagnostic or medical settings.

• Applied Use of (-)-JQ1: Rigorous Controls for BET Inhibition

  2026-05-03

  (-)-JQ1, the inactive JQ1 stereoisomer, is indispensable for benchmarking specificity in BET bromodomain inhibition studies. By distinguishing on-target from off-target effects, it empowers researchers in epigenetics and cancer biology to achieve reproducible, interpretable results—especially in BRD4-dependent workflows.

• Optimized hiPSC Platelet Differentiation: Protocol and Src I

  2026-05-02

  This study introduces a systematically optimized protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs), integrating small molecule modulation—including Src tyrosine kinases inhibition—to boost yield and efficiency. The findings highlight cost-effective, scalable strategies for ex vivo platelet production, with direct implications for cell therapy and regenerative medicine.

• RNA Pol II Inhibition Triggers Apoptosis Independent of Tran

  2026-05-01

  Harper et al. (2025) reveal that cell death after RNA Pol II inhibition is initiated by the loss of its hypophosphorylated form (RNA Pol IIA), not by the cessation of transcription. This discovery reframes how apoptosis is triggered in cancer cells and highlights new mechanistic targets for anticancer therapy.

• Ferroptosis Inducers Target Advanced Prostate Cancer: RSL3 I

  2026-05-01

  This study establishes ferroptosis inducers, particularly RSL3, as promising therapeutic agents against advanced, treatment-resistant prostate cancer. By demonstrating the efficacy of glutathione peroxidase 4 inhibition in halting tumor growth and overcoming androgen-targeted therapy resistance, the research paves the way for new intervention strategies in aggressive prostate malignancies.

• AO/PI Staining Solution: Precision in Cell Viability for Com

  2026-04-30

  Explore how AO/PI Staining Solution leverages fluorescent DNA dyes for precise cell viability analysis in advanced disease models. This article uniquely connects mechanistic assay fidelity with recent research on diabetic nephropathy, delivering technical insights and practical protocols.

• Palonosetron Hydrochloride: Advanced Workflows for 5-HT3 Ant

  2026-04-30

  Palonosetron hydrochloride redefines precision in 5-HT3 receptor antagonist research, offering unmatched selectivity and prolonged efficacy for both antiemetic studies and transporter inhibition. Its dual-site allosteric mechanism and extended half-life support robust, reproducible workflows across in vitro and in vivo models.

• Patient-Derived Gastric Cancer Assembloids Model Tumor Compl

  2026-04-29

  This study introduces a gastric cancer assembloid model integrating matched tumor organoids and stromal cell subpopulations, enabling a closer recapitulation of tumor microenvironmental complexity. The platform advances our ability to study drug response variability and resistance mechanisms, supporting more physiologically relevant preclinical testing.

• Ciprofloxacin in Research: Protocols, Applications, and Trou

  2026-04-29

  Ciprofloxacin, a benchmark fluoroquinolone antibiotic, is transforming experimental workflows in antimicrobial resistance and advanced theranostic research. This article distills validated protocols, innovative applications, and actionable troubleshooting for maximizing data quality with APExBIO’s high-purity Ciprofloxacin.

• HA-LNP Delivery of PTEN mRNA Enables Transdermal Cancer Immu

  2026-04-28

  This study introduces hyaluronate-conjugated lipid nanoparticles (HA-LNPs) for the transdermal delivery of PTEN mRNA, restoring tumor suppressor function and enhancing immunotherapy efficacy in melanoma models. The approach addresses key barriers in mRNA delivery, demonstrating significant tumor inhibition and immune activation with minimal toxicity.

• Adiponectin Mitigates Post-Surgical Cognitive Decline via TL

  2026-04-28

  This study demonstrates that adiponectin treatment attenuates splenectomy-induced cognitive deficits in aged rats by suppressing neuroinflammation and oxidative stress through the TLR4/MyD88/NF-κB pathway. Findings highlight a mechanistic avenue for perioperative neurocognitive disorder intervention and inform peptide-based research strategies.

• Metformin-Induced Vasorelaxation via EDH in Colitis: Mechani

  2026-04-27

  This article synthesizes the novel mechanisms underlying metformin-induced vasorelaxation in mesenteric arterioles, with a focus on endothelium-dependent hyperpolarization (EDH) pathways in health and murine colitis models. The findings provide a mechanistic basis for metformin's protective effects in colitis and highlight methodological advances relevant for cardiovascular and gastrointestinal research.

• BMS-345541 Hydrochloride: Advanced IKK Inhibition in Inflamm

  2026-04-27

  Explore the molecular precision of BMS-345541 hydrochloride as a selective IKK inhibitor for inflammation research. This article delivers a uniquely deep analysis of its mechanism, experimental optimization, and translational value for cancer biology and T-ALL studies.

• CAFs-Derived Fatty Acids Drive Lipid Raft-Mediated OSCC Prog

  2026-04-26

  This study demonstrates that cancer-associated fibroblasts (CAFs) secrete free fatty acids (FFAs) that are taken up by oral squamous cell carcinoma (OSCC) cells, promoting lipid raft formation and activating oncogenic PI3K/AKT signaling. These findings highlight the metabolic interplay within the tumor microenvironment and suggest new therapeutic targets to limit OSCC progression.

• Capecitabine in Translational Oncology: Mechanisms & Models

  2026-04-25

  Explore how Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) is redefining preclinical oncology research. This article blends mechanistic insights, recent assembloid model advances, and practical guidance for translational researchers seeking to model chemotherapy selectivity and tumor-targeted delivery with high physiological relevance.

16189 records 1/1080 page Next 12345 下5页 Last page